Tamoxifen is a selective oestrogen receptor modulator used in pre-menopausal oestrogen receptor positive breast cancer patients as adjuvant endocrine treatment. Increased risk of venous thromboembolism with the use of Tamoxifen is well known from published literature. This risk further increases in patients undergoing surgical procedures of high risk involving prolonged period of immobilization, therefore withholding Tamoxifen treatment in the immediate peri-operative period should be considered as a risk reducing measure. In the absence of nationally agreed guidelines on the safe duration for stoppage of treatment in the pre and post operative period without worsening cancer prognosis, operating surgeons and individual trusts have adopted their own guidelines based on individual experience. From the available evidence in the literature on the VTE risk assessments based on age, operative procedure and pharmacokinetics of the Tamoxifen drug we would like to propose a working algorithm for selecting the right patient group and safe treatment stoppage durations. These proposed guidelines are formulated taking all the risk factors of VTE, operative risks, pharmacokinetics of the drug and chemotherapy risks into consideration. With this guidance, we aim to help surgeons across different specialities in the decision making process through a structured evidence based approach.
Introduction
Tamoxifen is an oestrogen receptor modulator, selectively binding and antagonising oestrogen effects. Tamoxifen is routinely used in oestrogen receptor (ER) positive breast cancers as adjuvant endocrine therapy post surgery in pre-menopausal women. Increased risk of venous thrombo-embolism (VTE) associated with tamoxifen treatment is well known from various studies. 1e4 The
International Breast Cancer Intervention Study (IBIS) and European Institute of Oncology trials have shown a 2.3 fold increased risk of venous thrombo-embolism in women treated with tamoxifen compared to placebo. 5 Other associated independent factors such as obesity, atherosclerosis, factor V Leiden 6,7 prothrombin mutation and smoking further increase the risk of Tamoxifen induced VTE. Fig. 1 A search for evidence based guidelines on stoppage duration of Tamoxifen in breast cancer patients during the perioperative period to reduce the risk of VTE was carried out from Pub Med and MEDLINE databases. Search terms like "guidelines on Tamoxifen stoppage in perioperative period", "Tamoxifen stoppage duration and postoperative VTE incidence" and "Tamoxifen and duration of surgery" showed no previous publications on the related topic.
Aim
To establish an algorithm for patient selection and safe stoppage duration of Tamoxifen treatment pre-operatively in breast cancer patients undergoing surgical interventions.
Our proposed algorithm is derived in the light of the clinical evidence of increased risk of VTE with different surgical procedures and individual risk factors; along with these, recent chemotherapy treatment and duration of surgical procedure have also been considered.
Evidence on perioperative VTE risk
The risk of VTE is increased by having cancer; studies have shown a 4-fold increased risk of VTE average across all the cancers with an annual reported incidence of approximately 0.48%. This risk is increased further in patients having surgery immediately after finishing breast chemotherapy, 8 with an overall estimated risk of 0.16% within 60 days after the procedure. Data from the large prospective cohort study "The Million Women Study" 9 indicated "a substantial increased risk of VTE in first 12 weeks after in-patient operations and 6 weeks after day-surgery". This risk was found to be highest for joint replacement and cancer surgery. The overall risk conclusions from this study showed an increase of 70 and 10 fold following in-patient and day-surgeries in comparison to women not having any surgery during the study period. Evidence for continuing VTE prophylaxis (Mechanical and Pharmacological) after surgery in cancer patients comes from National Institute of Clinical Evidence (NICE).
14 It can be adopted for both day-case and in-patient surgery carried out under General Anaesthesia (GA). Pharmacological prophylaxis using "Low Molecular Weight Heparin (LMWH) should continued until the patient's mobility is no longer significantly impaired in the absence of any major risks of bleeding from surgery." This time period is about 5e7 days. Extended pharmacological prophylaxis for 28 days is recommended after major cancer surgery in the abdomen and pelvis. Surgical procedures performed under Local Anaesthesia do not need any VTE prophylaxis in the absence of impaired mobility even in the cancer patients.
Correlation between tamoxifen and VTE incidence after surgery
The only published evidence to date on the incidence rates of VTE after breast surgery comes from the NHS hospital episode statistics database 15 from year 2004, this data holds the record of every patient admitted to NHS hospital in England with secondary symptomatic deep vein thrombosis or pulmonary embolisms following various surgical procedures. Summarized below (Table 1) are the results from total of 22 episodes in a sample size of 78,547 patients recorded, accounting for an overall risk of 0.03%. Patient groups included in the registry have been mentioned to have received some form of thrombo prophylaxis following surgical procedures; with no definite details on type and duration of thrombo prophylaxis mentioned. The risk of VTE increases significantly in breast cancer patients following any surgical procedure if patients had been on recent chemotherapy or using Tamoxifen for long. This risk was found to be 0.8% within 6 weeks of surgery after breast chemotherapy from the Clahsen et al. study group, 10 
Evidence for the need of guidelines
In the light of established evidence pointing towards increased VTE risk with tamoxifen and a further increment of this risk with surgery and recent chemotherapy treatment, stopping tamoxifen in the perioperative period should be considered as the best safe practice in high risk cases. Determining safe stoppage duration for tamoxifen before surgery without worsening the cancer prognosis remains a challenge. In the absence of nationally agreed guidelines regarding, universally agreed protocols across health services are difficult to implement. Hence, one assumes that every hospital follows local protocols in this regard based on the individual VTE risk stratification and experience of the operating surgeon; this approach has potential to result in significant practice variations.
The Committee on Safety of Medicines (CSM), an independent advisory body for UK licensing authorities on safety of prescribing medicines, have recommended (pharmacovigilance guidance; 2002) 16 continuation of tamoxifen therapy before surgery or following long-term immobility, unless the risk of tamoxifeninduced thrombosis outweighs the risk of interrupting the treatment in breast cancer patients. In situations warranting treatment suspension, surgeons are advised to consider cancer stage, grade, duration and clinical response to therapy at the time of decision making. However, since this guidance was published, there have been overwhelming evidence from trials (NSABP-1, EORTC) and observational studies (The Million Women) linking the preoperative use of tamoxifen to an increased risk of VTE following surgery. This risk remains high up to 12 weeks following in-patient and up to 6 weeks after day surgery under GA. In the light this and further new evidence on the heightened risk with recent chemotherapy treatment 10,11 the old CSM recommendations require revision. Further, CSM guidance has a potential to be interpreted and accepted as a generic recommendation in the absence of patient or procedure exclusion criteria leaving the door open to some variability in understanding the guidance. Our proposed algorithm on stoppage durations in the perioperative period have been devised taking into consideration all the above factors and different patient groups. Patient selection based on VTE risk stratification is derived from the National Clinical Guidelines Centre Group (NCGC) criteria (Table 3) . In order to determine the safe stoppage and restart times of tamoxifen prior to and after surgery we have considered the pharmacokinetics of the drug. 13 Following administration of a single oral dose of 20 mg of tamoxifen, the average peak plasma concentration is achieved within approximately 5 h. Tamoxifen is extensively metabolized to N-desmethyltamoxifen in the plasma, which has a similar biological activity to tamoxifen. Chronic administration of 10 mg twice daily or 20 mg single dose daily of tamoxifen achieves a steady plasma state concentration of both tamoxifen and its active metabolite in 4 and 8 weeks period respectively. The decline in plasma concentration follows a biphasic pattern with an elimination half life of 7e14 days. Tamoxifen is primarily excreted in faeces with 65% of the administered dose excreted over a period of 2 weeks. Therefore approximately 98% of the drug would be fully eliminated from the plasma by 3 weeks. The decision to restart tamoxifen in the post operative period is complex and dependent on various factors, mostly related to patient's general condition, cancer stage, nature and duration of surgical procedure performed. The guidance from NICE on the perioperative risk of VTE from different surgical operations across various specialities should also be considered before arriving at the decision. Following major surgery like joint replacement, tamoxifen is stopped for 3 weeks prior and after the procedure. This time period is determined based on the nature of surgery (high risk for VTE) and also the duration of rehabilitation. Generally this period of tamoxifen stoppage is considered acceptable without any major risk of cancer progression or recurrence; although conclusive evidence is lacking. The overall risk of VTE for patients on tamoxifen undergoing breast surgery is low, following the generic guidance on VTE risk reduction i.e. using mechanical prophylaxis TED stockings and flowtrons boots in the peri and post operative period a further minimization of the risk can be achieved.
Operative duration is a risk factor for VTA. NCGC guidance recommends the use of pharmacological thrombo prophylaxis for general surgical procedures lasting more than 90 min or limb and pelvic surgeries lasting more than 60 min. There is no reported evidence considering ASA grade in itself as an independent risk factor for VTE, although recovery times are known to be longer in higher ASA grade elderly patients following surgery. 17 This on its own can be a significant risk factor for post operative VTE, therefore thrombo prophylaxis in such patient groups should be considered even after a low risk surgical procedure.
Conclusion
Tamoxifen treatment interruption may be required prior to some surgical procedures. There are no definitive guidelines on the duration of stopping medication pre and post operatively. We therefore would like to propose a framework of guidelines based on the best available evidence from clinically relevant studies and pharmacological evidence. Our proposed guidelines are summarized in the flow chart below.
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